Life Sciences
Our life sciences specialists have an in-depth understanding of the corporate, commercial, intellectual property and employment issues affecting this sector.
The cross-firm team provides the range of legal services required by clients across the industry spectrum, from biotechnology, pharmaceuticals and medical devices companies to institutions or organisations that are involved in the research, development and sale of medicines, medical devices or nutritional products.
We advise on all aspects of UK and international acquisitions, disposals, joint ventures, developments and other transactions undertaken by clients, including structuring and financing, and have experience of public market fundraisings for many life science businesses.
Our expertise extends to all related areas of commercial activity, with the team advising on product licensing, manufacturing and distribution agreements, as well as IP protection and commercialisation.
If you have any questions or queries please call Nigel on +44 (0)20 3036 7389 or email ngordon@fladgate.com
Chambers UKInternational-flavoured practice handling a wide range of transactions.
Industries
The employment team at Fladgate LLP “saw substantial growth in 2015 with the recruitment of Michael McCartney … The team recently advised Alliance Pharma on the employment elements of its acquisition of 27 products from Sinclair Pharma.”
Legal 500
Fladgate LLP’s “approach is pragmatic and constructive”, with its “very knowledgeable lawyers providing excellent service”.
Legal 500
Nigel Gordon is “a capital markets lawyer with a great deal of experience advising AIM and TSX-listed clients on finance and M&A activity”.
Chambers UK
Chris Chrysanthou is “praised for being practical and outcome-focused”.
Legal 500
Fladgate LLP advises on a broad variety of contracts… A “high level of service and quality” is provided by the eight-partner [commercial] team, led by Eddie Powell.
Legal 500
Michael McCartney led advice to Alliance Pharma on the employment aspects of its acquisition of Macuvision.
Legal 500
International-flavoured practice handling a wide range of transactions… “Excellent and client-driven with senior partners leading from the front in the management and delivery of transaction advice.”
Chambers UK
‘Excellent in terms of being able to understand the problems at hand and provide pragmatic advice’, Fladgate LLP’s ‘versatile’ department is regularly called on to handle the employment aspects of complex transactions with a multi-jurisdictional element. Michael McCartney led advice to Ipsen Biopharmaceuticals on the relocation of 60 employees from Slough to Oxford.
Legal 500
- Alliance Pharma – acquisition of companies and products, including the non-aesthetics business of Sinclair IS Pharma plc for £131m.
- Synairgen – admission to AIM and a £10.5m placing.
- Oxford Pharmascience – placing of new ordinary shares and admission to AIM, together with a secondary placing raising £20m.
- Medgenics – advising the nominated adviser and broker on the admission of Medgenics to trading on AIM together with a placing.
- Toumaz – advising this AIM listed company on its digital plaster technology.
- Morria Biopharmaceuticals – listing of American Depositary Receipts on the US OTC Bulletin.
- Life sciences venture capital companies – advising investors on the disposal of its investments in three life sciences venture capital companies based in England, Cyprus and India to a large US life sciences company for a value of over US$18.5m.
- Wanbury Limited – listing of €15m of unsecured foreign currency convertible bonds on the Luxembourg Stock Exchange for this Indian pharmaceutical company.
- Neubourg Skin Care – joint venture arrangements in relation to UK market entry.
- Celsus Therapeutics – public offering of American Depositary Shares on NASDAQ for this emerging growth, development-stage biotech company.
- GeneOnyx and its UK operating subsidiary Geneu – negotiation of supply agreements with several key packaging and product suppliers, including the provision of testing chips from the manufacturer, and an exclusive licence to market the technology in the consumer cosmetic space.
- Canopus Biopharma – restructuring of its IP licensing in relation to the clinical trials of OLTIPRAZ and MOGROSIDES drugs.
- Ipsen, Takeda and Alliance Pharma – various employment matters.
Accreditations
